Mentoring in Advanced mHealth Technologies and Machine Learning for HIV/Drug Abuse Research

指导艾滋病毒/药物滥用研究的先进移动医疗技术和机器学习

• 批准号: 10529984
• 负责人: Edward W Boyer
• 金额: $ 19.13万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-11-19 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10529984
• 关键词: Mentoring; Advanced; mHealth; Technologies; Machine

Abstract Renewal of my Midcareer Investigator Award in Patient-Oriented Research (K24) will allow me to continue my strong efforts directed toward successful original investigations and mentoring to generate research capacity in mobile technologies to improve health (mHealth). The impact of the initial K24 on my mentees has been striking. Since award of the initial K24, nearly two dozen of my mentees, 70% of whom are women or minorities, have been PI on NIH funded studies (under K, R, or Loan Repayment Program mechanisms). The impact the K24 on my own research has been substantial. Since 2014, I have been Principal Investigator (PI) on six federally funded awards: 1) one newly funded 4-year R01 from NIDA; 2) one R56 from NIDA; 3) one two-year R01 from NIDA; 4) one 4-year R01 from NIDA; 5) my K24 from NIDA; and 6) one newly funded 4-year DARPA research award. In addition, I received a William J Fulbright Foreign Scholarship to Malaysia. As my K24 evolved, so has my research focus. My overall research objective is to devote sufficient time to investigate use of next generation (“NextGen”) technologies, invisible biosensing, and machine learning in substance abuse and HIV research. My first research project, Virya, uses “digital phenotyping” with invisible biosensing and machine learning, to identify acute pain exacerbations in HIV+ individuals on opioids, a population at risk for problematic opioid use. The second reseach project uses mobile technologies to diagnose Covid-19 infection in HIV+ persons who inhale cannabis, itself a high-impact topic. Finally, the R01-funded MyTPill project compares the NextGen technology of unobtrusive ingestible biosensors that provide vivid, indisputable measures of medication ingestion. NextGen research discoveries become commercial products, but this process of introducing new discoveries into the healthcare economy remains deeply unfamiliar—yet increasingly important— to academic clinician-scientists. The objective of my Career Development Activities, therefore, involves learning how to navigate regulatory processes, FDA approvals, valuations, venture capital, contracts and intellectual property rights. Because of the growing importance of commercialization of research findings to the health and sustainability of academic careers, my overall mentoring objective of this K24 is to develop researchers who not only have the skills to conduct rigorous NextGen mHealth studies, but also to extend the mass of NIH-funded mHealth research into the healthcare economy. My mentoring approach incorporates several components that contributed to the success of my initial K24: dedicated funding for mentee’s early investigations; outstanding institutional support; several sources of referral of high-quality mentees; and renowned co- mentors who will help me establish a pipeline of mentees that have risen to that “cutting edge” where successful academic careers begin. This proposed K24 renewal, with its focus on NextGen technologies, invisible biosensing, and machine learning, is highly relevant to NIH’s mission because the lessons learned from this substance abuse and HIV research are directly applicable to the care of patients with common, intractable, and expensive conditions.

抽象的 续签我的中级护理研究员授予患者的研究奖（K24）将使我继续努力 致力于成功的原始调查和心理，以创造移动技术的研究能力 改善健康状况（MHealth）。最初的K24对我的月经的影响令人震惊。自授予初始K24以来 我的麦内斯（Menees）中有近二十二个是妇女或少数族裔，是NIH资助的研究（根据K，R，R， 或贷款还款计划机制）。 K24对我自己的研究的影响很大。自2014年以来，我 曾是六项联邦资助奖项的首席研究员（PI）：1）一项来自NIDA的新资助的4年R01； 2）一个R56 来自NIDA； 3）NIDA的一份为期两年的R01； 4）来自NIDA的4年R01； 5）我来自NIDA的K24； 6）一个新资助 4年DARPA研究奖。此外，我还获得了马来西亚的William J Fulbright外国奖学金。作为我的K24 进化，我的研究重点也是如此。我的总体研究目标是花费足够的时间调查下一个的使用 一代（“ NextGen”）技术，无形的生物传感和药物滥用和艾滋病毒研究中的机器学习。我的 第一个研究项目Virya使用“数字表型”和无形的生物传感和机器学习，以识别急性疼痛 艾滋病毒+个体对阿片类药物的加剧，这是有问题的阿片类药物使用风险的人群。第二个参考项目 使用移动技术来诊断吸气大麻的艾滋病毒+人中的Covid-19感染本身就是一个高影响的话题。 最后，R01资助的MyTPILL项目比较了提供的不引人注目的可观生物传感器的NextGen技术 生动的，无可争议的药物摄入量度。 NextGen研究发现成为商业产品，但这 将新发现引入医疗保健经济的过程仍然非常陌生 - 但越来越重要 - 到学术临床科学家。因此，我职业发展活动的目标包括学习如何 导航监管流程，FDA批准，估值，风险投资，合同和知识产权。因为 我 该K24的总体心理目标是发展研究人员，他们不仅具备进行严格的NextGen技能 MHealth研究，但也将大量由NIH资助的MHealth研究扩展到医疗保健经济中。我的想法 方法结合了几个组件，这些组件有助于我最初的K24的成功：对受训者的专门资金 早期调查；出色的机构支持；高质量月经转诊的几个来源；和著名的共同 将帮助我建立一群梅内特的导师 职业开始。这提出了K24续订，重点是NextGen技术，无形的生物传感和机器 学习与NIH的使命高度相关，因为从这种药物滥用和艾滋病毒研究中吸取的教训是 直接适用于患有常见，顽固且昂贵疾病的患者的护理。